Gastroesophageal Reflux Disease Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Gastroesophageal Reflux Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Gastroesophageal Reflux Disease (GERD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Gastroesophageal Reflux Disease Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Gastroesophageal Reflux Disease Pipeline Report

* On January 15, 2026- Microbiome Health Sciences initiated a study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
* On January 14, 2026- Takeda announced a study is called dexlansoprazole. Dexlansoprazole is being tested to treat children aged 2 to 11 years who have nonerosive GERD. This study will look at the effectiveness and side effects of three different doses of dexlansoprazole in children with GERD. The study will enroll approximately 70 patients. Participants weighing less than or equal to 30 kilograms (kg) will be randomly assigned (by chance, like flipping a coin) to receive dexlansoprazole 15 or 30 milligrams (mg), and participants who weigh >30 kg will be randomized to receive dexlansoprazole 30 or 60 mg.
* DelveInsight's Gastroesophageal Reflux Disease Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Gastroesophageal Reflux Disease treatment.
* The leading Gastroesophageal Reflux Disease Companies such as Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation and others.
* Promising Gastroesophageal Reflux Disease Therapies such as AH23844 (lavoltidine), NEXIUM (esomeprazole), ZANTAC (ranitidine), Aflurax, Esomeprazole, Pantoprazole, Famotidine, Tegoprazan and others.

Want to know which companies are leading innovation in Gastroesophageal Reflux Disease? Dive into the full pipeline insights @ Gastroesophageal Reflux Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Gastroesophageal Reflux Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gastroesophageal Reflux Disease Pipeline Report also highlights the unmet needs with respect to the Gastroesophageal Reflux Disease.

Gastroesophageal Reflux Disease Overview

Gastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. It is one of the most commonly diagnosed digestive disorders in the US with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life. Currently, there is no known cause to explain the development of GERD. Over the years, several risk factors have been identified and implicated in the pathogenesis of GERD.

Gastroesophageal Reflux Disease Emerging Drugs

* X842: Cinclus Pharma

X842 represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion. X842 is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca. Linaprazan has been evaluated in 23 phase I, and two phase II studies in a total of approximately 2,500 subjects. X842 is being developed for treatment of severe Gastroesophageal reflux disease (GERD) and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs. In comparison, X842 has a longer half-life in the body, shows total control of the gastric acid production, and is tailored for patients with severe eGERD.

* Zastaprazan: Onconic Therapeutics

Zastaprazan is a P-CAB (potassium-competitive acid-blocking) class drug candidate, which is currently replacing existing PPIs (proton pump inhibitors) in the market for peptic ulcer disease, including GERD. Unlike PPI drugs, P-CABs bind directly to potassium ions without the need for activation by stomach acid. It blocks the secretion of gastric acid by interfering with the binding of potassium ions to the proton pump. It can be taken with or without meals and has a longer duration of action than existing therapies, making it highly preferred by both physicians and patients. Meanwhile, in Korea, Onconic began a phase 3 clinical trial for reflux esophagitis for Zastaprazan in January last year. The company expects to launch the drug in Korea by 2024.

If you're tracking ongoing Gastroesophageal Reflux Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Gastroesophageal Reflux Disease Treatment Drugs [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Gastroesophageal Reflux Disease Companies

Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation and others.

The Gastroesophageal Reflux Disease Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Gastroesophageal Reflux Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroesophageal Reflux Disease Treatment.
* Gastroesophageal Reflux Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Gastroesophageal Reflux Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroesophageal Reflux Disease market.

Gastroesophageal Reflux Disease (GERD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Gastroesophageal Reflux Disease Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

From emerging drug candidates to competitive intelligence, the Gastroesophageal Reflux Disease Pipeline Report covers it all - check it out now @ Gastroesophageal Reflux Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Gastroesophageal Reflux Disease Pipeline Report

* Coverage- Global
* Gastroesophageal Reflux Disease Companies- Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation and others.
* Gastroesophageal Reflux Disease Therapies- AH23844 (lavoltidine), NEXIUM (esomeprazole), ZANTAC (ranitidine), Aflurax, Esomeprazole, Pantoprazole, Famotidine, Tegoprazan and others.
* Gastroesophageal Reflux Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Gastroesophageal Reflux Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Gastroesophageal Reflux Disease Treatment landscape in this detailed analysis @ Gastroesophageal Reflux Disease Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Gastroesophageal Reflux Disease (GERD): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Gastroesophageal Reflux Disease (GERD) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Zastaprazan: Onconic Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* X842: Cinclus Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* IN-C005: HK inno.N
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Gastroesophageal Reflux Disease (GERD) Key Companies
* Gastroesophageal Reflux Disease (GERD) Key Products
* Gastroesophageal Reflux Disease (GERD)- Unmet Needs
* Gastroesophageal Reflux Disease (GERD)- Market Drivers and Barriers
* Gastroesophageal Reflux Disease (GERD)- Future Perspectives and Conclusion
* Gastroesophageal Reflux Disease (GERD) Analyst Views
* Gastroesophageal Reflux Disease (GERD) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastroesophageal-reflux-disease-treatment-pipeline-shows-strong-momentum-as-10-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.